written by reader Curing Obesity by Dave Lashmet with Stansberry Venture Technology

By chiefalbob, August 26, 2020

It’s the stock of a tiny, little-known pharmaceutical company, trading for less than $50 a share. This company controls a potential cure for the obesity epidemic.
Dave has done the research, dating back four years. He’s one of a handful of people outside this company’s headquarters who are aware of what’s going on and the nuances of this drug’s development, approval process, and why the company has been so secretive about it.
This drug turns down our natural “hunger switch.” It essentially gives you a higher metabolism. It’s a potentially world-changing drug, and it’s completely under the radar… but won’t be for much longer.

This is a discussion topic or guest posting submitted by a Stock Gumshoe reader. The content has not been edited or reviewed by Stock Gumshoe, and any opinions expressed are those of the author alone.

guest

12345

This site uses Akismet to reduce spam. Learn how your comment data is processed.

5 Comments
Inline Feedbacks
View all comments
macrobody
macrobody
27 days ago

Maybe ENTA (Enanta) Around $50 and doing something in the obesity field if I understand correctly.
https://www.enanta.com/research/nash/default.aspx

Add a Topic
4482
πŸ‘ 92
Dave S
Dave S
27 days ago
Reply to  macrobody

I don’t think ENTA is it. Their research is in Fatty Liver disease not cause by alcohol. The other research refers to respiratory viruses and hepatitus B. I don’t see anything where they are working on obesity.

macrobody
macrobody
27 days ago
Reply to  Dave S

Indeed. I was wrong. Travis has already solved it!

πŸ‘ 92
πŸ‘ 15814
Dee Kay
Dee Kay
27 days ago

I say it is Rhythm Pharmaceuticals RYTM. I have seen his video at Dailywealth.com.
Go to to Biospace.com and enter Rhythm.
Go to Seekingalpha.com and enter the symbol. On the page showing the price chart look for
“Investor Presentation Slide Show.”
I think the drug is setmelanotide.

We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

More Info